Nancy E. Lane, MD
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Safety and Tolerability of Intravenous LLP2A-Alendronate for Osteopenia Secondary to Glucocorticoids (NCT03197623) | Nancy E. Lane, MD | 2016-10-14 |
Track Nancy E. Lane, MD automatically
Every clearance here is in the API, with alerts when new ones post.